HR Execs on the Move


 
We`re the Life Sciences newcomer you already know. Cytiva is bringing our long-standing expertise to the forefront of science, to fuel research, discovery, and development with technologies, instruments, and software. We drive customer-centered innovation in 11 facilities across Asia, Europe and America from idea to commercial development stages.
  • Number of Employees: 5K-10K
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Anita Desai
Director, Human Resources Profile
Anton Moskalenko
Director, Global HR Associate Care Profile
Matt McClelland
VP, Marketing and Strategy, Discovery and Medical Profile
Dustin Crumby
Director of Marketing Operations Profile
Amy Osier
Vice President of Human Resources for BioProcessing Profile

Similar Companies

IMS Group

IMS Group is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

NextImage Medical

NextImage Medical, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

MicroGEM

At MicroGEM, we are transforming the landscape of DNA and RNA extraction. Come see how our single-tube extraction workflows can work for you!

Maxim Health Information Services

Maxim Health Information Services is a Gardena, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NMD Pharma

NMD Pharma A/S is a clinical-stage biotech company developing a first-in-class platform of small molecule therapies selectively targeting the skeletal muscle chloride ion channel (ClC-1) for the treatment of severe neuromuscular disorders. The Company was incorporated as a spin-off from Aarhus University, Denmark in 2015 and was founded on more than 15 years of muscle physiology research with a focus on regulation of skeletal muscle excitability under physical activity. NMD Pharma has built a world-leading muscle electrophysiology platform leveraging the in-depth know-how of muscle physiology and muscular disorders, small molecule modulators, enabling technologies and tools as well as in vivo pharmacology models for discovering and developing proprietary modulators of neuromuscular function. NMD Pharma received initial seed financing in 2016 and has since raised ~€155 million from investors including Novo Holdings, Lundbeckfonden BioCapital, INKEF Capital, Roche Venture Fund, and Jeito Capital.